

Sylvie Lorenzen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1405212/publications.pdf>

Version: 2024-02-01

23
papers

615
citations

759233

12
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

877
citing authors

#	ARTICLE	IF	CITATIONS
1	The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. <i>BMC Cancer</i> , 2017, 17, 893.	2.6	128
2	Prognostic Significance of Free Peritoneal Tumor Cells in the Peritoneal Cavity Before and After Neoadjuvant Chemotherapy in Patients with Gastric Carcinoma Undergoing Potentially Curative Resection. <i>Annals of Surgical Oncology</i> , 2010, 17, 2733-2739.	1.5	89
3	Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 2119-2127.	1.5	62
4	Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. <i>European Journal of Cancer</i> , 2015, 51, 569-576.	2.8	59
5	Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).. <i>Journal of Clinical Oncology</i> , 2020, 38, 96-96.	1.6	41
6	RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. <i>BMC Cancer</i> , 2020, 20, 886.	2.6	32
7	PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. , 2021, 9, e002844.		29
8	Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III –PREVENT– (FLOT9) trial of the AIO /CAOGI /ACO. <i>BMC Cancer</i> , 2021, 21, 1158.	2.6	23
9	Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). <i>International Journal of Cancer</i> , 2020, 147, 2493-2502.	5.1	22
10	Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): The Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. <i>BMC Cancer</i> , 2011, 11, 266.	2.6	21
11	Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1203.	7.1	19
12	Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 90, 26-33.	2.8	17
13	Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 263-272.	3.0	16
14	FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. <i>European Journal of Cancer</i> , 2022, 165, 48-57.	2.8	15
15	Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 123, 101-111.	2.8	10
16	A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4027-4027.	1.6	10
17	Influence of Taxanes on Treatment Sequence in Gastric Cancer. <i>Oncology Research and Treatment</i> , 2020, 43, 42-47.	1.2	8
18	Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0153943.	2.5	8

#	ARTICLE	IF	CITATIONS
19	Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.. <i>Journal of Clinical Oncology</i> , 2020, 38, 398-398.	1.6	3
20	FOLFOX versus FOLFOX plus nivolumab and ipilimumab administered in parallel or sequentially versus FLOT plus nivolumab administered in parallel in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase 2 trial of the AIO.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4043-4043.	1.6	2
21	Immunotherapy: New Options in Gastrointestinal Cancers?. <i>Visceral Medicine</i> , 2019, 35, 47-51.	1.3	1
22	Multimodale Therapie bei Karzinomen des gastroösophagealen Öbergangs (GÖÖ). <i>Onkopipeline</i> , 2009, 2, 92-100.	0.0	0
23	Impact of pathologic complete response to preoperative docetaxel-based chemotherapy on disease-free survival in esophagogastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 123-123.	1.6	0